Management of refractory inflammatory bowel disease

Gergely, M; Prado, Eric A.; Deepak, Parakkal

doi:10.1097/mog.0000000000000849

Cited by 9 publications

(5 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, current treatment strategies, such as aminosalicylates, corticosteroids, immunosuppressants, and novel biologics, aim to manage symptoms and reduce inflammation. However, these treatments have several adverse side effects and are not always effective in some refractory cases (Silvio et al 2022;Mate et al 2022). Therefore, a promising approach is urgently required for IBDs.…”

Section: Introductionmentioning

confidence: 99%

Wogonin preconditioning of MSCs improved their therapeutic efficiency for colitis through promoting glycolysis

Wu,

Li,

Zhou

et al. 2024

Inflammopharmacol

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are prevalent and debilitating diseases with limited clinical treatment strategies. Mesenchymal stem cells (MSCs) are pluripotent stem cells with selfrenewal capability and multiple immunomodulatory effects, which make them a promising therapeutic approach for IBDs. Thus, optimization of MSC regimes is crucial for their further clinical application.Wogonin, a flavonoid-like compound with extensive immunomodulatory and adjuvant effects, has been investigated as a potential pretreatment for MSCs in IBD treatment. This research aimed to compare the therapeutic effectiveness of MSCs pretreated with or without wogonin. Compared to untreated MSCs, MSCwogonin (pretreated with wogonin) showed greater effectiveness in the treatment of colitis. Further experiments revealed that wogonin treatment activated the AKT signaling pathway, resulting in higher cellular glycolysis. Inhibition of AKT phosphorylation by perifosine not only decreased glycolysis but impaired the therapeutic efficiency of MSCwogonin. Consistent with these results, qPCR data indicated that wogonin treatment induced the expression of immunomodulatory molecules IL-10, IDO, and AGR1, which were reduced by perifosine. Together, our data demonstrated that wogonin preconditioning strategy further augmented the therapeutic efficacy of MSCs via promoting glycolysis, which should be a promising strategy for optimizing MSC therapy in IBDs.

show abstract

Section: Introductionmentioning

confidence: 99%

Wogonin preconditioning of MSCs improved their therapeutic efficiency for colitis through promoting glycolysis

Wu,

Li,

Zhou

et al. 2024

Inflammopharmacol

View full text Add to dashboard Cite

show abstract

“…Among IBD, Crohn's disease has no cure, and many of the therapies available are limited by their cost, availability, and efficacy. For example, TNF blockers are newer systemic treatments for IBD, but approximately 30% of patients with Crohn's disease do not respond to these medications and among those who do initially respond, half eventually develop tolerance [2,3]. Additionally, like many other available IBD therapies, TNF blockers are complicated by poorly tolerated side effects associated with their systemic delivery [4].…”

Section: Introductionmentioning

confidence: 99%

Targeting Inflammation and Oxidative Stress to Improve Outcomes in a TNBS Murine Crohn’s Colitis Model

Apte,

Bardill,

Canchis

et al. 2024

Nanomaterials

View full text Add to dashboard Cite

Inflammation and oxidative stress are implicated in the pathogenesis of Crohn’s disease. Cerium oxide nanoparticle (CNP) conjugated to microRNA 146a (miR146a) (CNP-miR146a) is a novel compound with anti-inflammatory and antioxidative properties. We hypothesized that local administration of CNP-miR146a would improve colitis in a 2,4,6-Trinitrobenzenesulfonic acid (TNBS) mouse model for Crohn’s disease by decreasing colonic inflammation. Balb/c mice were instilled with TNBS enemas to induce colitis. Two days later, the mice received cellulose gel enema, cellulose gel with CNP-miR146a enema, or no treatment. Control mice received initial enemas of 50% ethanol and PBS enemas on day two. The mice were monitored daily for weight loss and clinical disease activity. The mice were euthanized on days two or five to evaluate their miR146a expression, inflammation on histology, and colonic IL-6 and TNF gene expressions and protein concentrations. CNP-miR146a enema successfully increased colonic miR146a expression at 12 h following delivery. At the end of five days from TNBS instillation, the mice treated with CNP-miR146a demonstrated reduced weight loss, improved inflammation scores on histology, and reduced gene expressions and protein concentrations of IL-6 and TNF. The local delivery of CNP-miR146a in a TNBS mouse model of acute Crohn’s colitis dramatically decreased inflammatory signaling, resulting in improved clinical disease.

show abstract

“…Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation with periods of remission and relapse [1] and categorized as ulcerative colitis, Crohn's disease, or indeterminate colitis based on a combination of clinical, endoscopic, and histologic data [1,2]. Currently, the gold standard for IBD diagnosis is ileocolonoscopy and esophagogastroduodenoscopy (EGD) combined with histology analysis [3]; however, novel machine and deep learning technologies present promising new avenues to significantly enhance our understanding of IBD and optimize remission standards to aim for better patient outcomes.…”

Section: Introductionmentioning

confidence: 99%

Machine and deep learning in inflammatory bowel disease

Zulqarnain¹,

Rhoads²,

Syed³

2023

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of reviewThe Management of inflammatory bowel disease (IBD) has evolved with the introduction and widespread adoption of biologic agents; however, the advent of artificial intelligence technologies like machine learning and deep learning presents another watershed moment in IBD treatment. Interest in these methods in IBD research has increased over the past 10 years, and they offer a promising path to better clinical outcomes for IBD patients.Recent findingsDeveloping new tools to evaluate IBD and inform clinical management is challenging because of the expansive volume of data and requisite manual interpretation of data. Recently, machine and deep learning models have been used to streamline diagnosis and evaluation of IBD by automating review of data from several diagnostic modalities with high accuracy. These methods decrease the amount of time that clinicians spend manually reviewing data to formulate an assessment.SummaryInterest in machine and deep learning is increasing in medicine, and these methods are poised to revolutionize the way that we treat IBD. Here, we highlight the recent advances in using these technologies to evaluate IBD and discuss the ways that they can be leveraged to improve clinical outcomes.

show abstract

Management of refractory inflammatory bowel disease

Cited by 9 publications

References 69 publications

Wogonin preconditioning of MSCs improved their therapeutic efficiency for colitis through promoting glycolysis

Wogonin preconditioning of MSCs improved their therapeutic efficiency for colitis through promoting glycolysis

Targeting Inflammation and Oxidative Stress to Improve Outcomes in a TNBS Murine Crohn’s Colitis Model

Machine and deep learning in inflammatory bowel disease

Contact Info

Product

Resources

About